Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration

NCT02036723 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Wet Age-related Macular Degeneration

Interventions

DRUG: Bevacizumab
DRUG: Ranibizumab

Sponsor

Biocad